

**UTILITY
PATENT APPLICATION
TRANSMITTAL**

(Only for new nonprovisional applications under 37 CFR 1.53, b)

Attorney Docket No.

LEX-0134-USA

First Inventor

Gregory Donoho et al.

Title

Novel Human Thrombospondin Repeat Proteins and
Polynucleotides Encoding the Same

Express Mail label No.

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

ADDRESS TO:Assistant Commissioner for Patents
Box Patent Application
Washington, DC 202311 ☐ Fee Transmittal Form (e.g., PTO/SB/17)

(Submit an original and a duplicate for fee processing)

2 ☐ Applicant claims small entity status.
See 37 CFR 1.27.3 ☒ Specification [Total Pages 27]
(preferred arrangement set forth below)

- Descriptive title of the invention
- Cross Reference to Related Applications
- Statement Regarding Fed sponsored R & D
- Reference to sequence listing, a table,
or a computer program listing appendix
- Background of the invention
- Brief Summary of the invention
- Brief Description of the drawings (if filed)
- Detailed Description
- Claim(s)
- Abstract of the disclosure

4 ☐ Drawing(s) (35 U.S.C. 113) [Total Sheets]

5 Oath or Declaration [Total Pages]

a ☒ Unexecuted (original or copy)b ☐ Copy from a prior application (37 CFR 1.63(d))
(for continuation/divisional with Box 17 completed)i. ☐ **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s)
named in the prior application, see 37 CFR
1.63(d)(2) and 1.33(b)6 ☐ Application Data Sheet. See 37 CFR 1.767 ☐ CD-ROM or CD-R in duplicate, large table or
Computer Program (Appendix)8 Nucleotide and/or Amino Acid Sequence Submission
(if applicable, all necessary)a. ☐ Computer Readable Form (CRF)

b. Specification Sequence Listing on:

i. ☐ CD-ROM or CD-R (2 copies), orii. ☒ paperc. ☐ Statements verifying identity of above copies**ACCOMPANYING APPLICATION PARTS**9 ☐ Assignment Papers (cover sheet & document(s))10 ☐ 37 CFR 3.73(b) Statement
(when there is an assignee) ☒ Power of Attorney11 ☐ English Translation Document (if applicable)12 ☐ Information Disclosure
Statement (IDS)/PTO-1449 ☐ Copies of IDS
Citations13 ☐ Preliminary Amendment14 ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)15 ☐ Certified Copy of Priority Document(s)
(if foreign priority is claimed)16 ☐ Other17. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,
or in an Application Data Sheet under 37 CFR 1.76.☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP)

of prior application No.:

Prior application information: Examiner:

Group/Art Unit:

For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under
Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference.
The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts.**18. CORRESPONDENCE ADDRESS**☒ Customer Number or Bar Code Label

(Insert Customer No. or Attach bar code label here)

or ☐ Correspondence address below

Name

Lance K. Ishimoto

PATENT TRADEMARK OFFICE

Address

4000 Research Forest Drive

City

The Woodlands

State

TX

Zip Code

77381

Country

Telephone

(281) 863-3333

Fax

(281) 364-0155

Name (Print Type)

Lance K. Ishimoto

Registration No. (Attorney/Agent)

41866

Signature

Date

February 15, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and
Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant
Commissioner for Patents, Box Patent Application, Washington, DC 20231